Seeking Alpha

Early-stage positive clinical trial results contribute incremental value to anxious shareholders of biotech companies by validating drugs in their pipelines. These gains are especially magnified when the trials are designed to deal with difficult to treat diseases such as lung cancer or human papillomavirus (HPV), in which there are vast needs for treatment. Earlier this month, shareholders of Clovis Oncology (CLVS) saw their holdings double in a single day when the company reported strong safety data at the 2013 American Society of Clinical Oncology (OTC:ASCO) meeting. This surge in Clovis's price had me wondering if Inovio (INO) longs would share the same success with the company's upcoming catalyst that resembles similar features to those...

Only subscribers can access this article, which is part of the PRO research library covering 3,766 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: